Loading...
Loading...
ImmunoCellular Therapeutics
IMUC
announced that ICT-107, its dendritic cell-based vaccine, demonstrated a
statistically significant increase in progression-free survival (PFS) in
patients with newly diagnosed glioblastoma multiforme (GBM) in its
randomized, placebo-controlled phase II trial. A comparison of PFS
between ICT-107 and placebo showed a statistically significant
difference in the Kaplan-Meier (K-M) curves favoring ICT-107 (p=0.014
two-sided, hazard ratio (HR)=0.56) in the intent-to-treat population of
all 124 randomized patients. The difference in the median
progression-free survival times between ICT-107 and placebo favored
ICT-107 and was two months in duration. For the per-protocol population
(117 of 124 patients receiving at least four induction vaccinations),
the K-M comparison p-value improved in treated patients to 0.0074
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in